Back to Journals » OncoTargets and Therapy » Volume 11

Prognostic role of HSF1 overexpression in solid tumors: a pooled analysis of 3,159 patients

Authors Wan T, Shao J, Hu B, Liu G, Luo P, Zhou Y

Received 10 October 2017

Accepted for publication 13 December 2017

Published 17 January 2018 Volume 2018:11 Pages 383—393

DOI https://doi.org/10.2147/OTT.S153682

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Carlos E Vigil


Tao Wan,1,* Jing Shao,1,* Bin Hu,2 Gang Liu,1 Peng Luo,1 Yanming Zhou1

1Department of Hepatobiliary & Pancreatovascular Surgery, 2Department of Clinical Laboratory Medicine, First Affiliated Hospital of Xiamen University, Xiamen, China

*These authors contributed equally to this work

Background and objective: HSF1 is reported to be overexpressed in various solid tumors and play a pivotal role in cancer progression. A meta-analysis was conducted to assess the potential prognostic role of HSF1 in patients with solid tumors.
Methods: An extensive electronic search of three databases was performed for relevant articles. The pooled hazard ratios (HRs) or odds ratios with their corresponding 95% CI were calculated with a random-effects model. Heterogeneity and publication bias analyses were also conducted.
Results: A total of 3,159 patients from 10 eligible studies were included into the analysis. The results showed that positive HSF1 expression was significantly correlated with poor overall survival in all tumors (HR=2.09; 95% CI: 1.62–2.70; P<0.001). Subgroup analysis revealed that there was a significant association between HSF1 overexpression and poor prognosis in esophageal squamous cell carcinoma (ESCC) (HR=1.83; 95% CI: 1.21–2.77; P=0.004), breast cancer (BC) (HR=1.52; 95% CI: 1.24–2.86; P<0.001), hepatocellular carcinoma (HR=3.02; 95% CI: 1.77–5.18; P<0.001), non-small-cell lung cancer (HR=2.19; 95% CI: 1.20–3.99; P=0.01), and pancreatic cancer (HR=2.58; 95% CI: 1.11–6.03; P=0.03) but not in osteosarcoma (HR=1.58; 95% CI: 0.47–5.35; P=0.46). In addition, HSF1 overexpression was significantly associated with some phenotypes of tumor aggressiveness including TNM stage, histological grade, lymph node metastasis, and vascular invasion.
Conclusion: HSF1 overexpression may prove to be an unfavorable prognostic biomarker for solid tumor patients.

Keywords:
HSF1, solid tumors, prognosis, overall survival, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]